최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0905236 (2014-07-18) |
등록번호 | US-9925144 (2018-03-27) |
국제출원번호 | PCT/US2014/047304 (2014-07-18) |
국제공개번호 | WO2015/010092 (2015-01-22) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 890 |
Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improve
Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.
1. An inhalable spray-dried powder pharmaceutical formulation comprising an oxytocin synthetic peptide, a derivative or analog of said peptide; zinc citrate or zinc chloride, and/or a pharmaceutically acceptable carrier or excipient, wherein the formulation is stable for at least 40 weeks at 40° C.
1. An inhalable spray-dried powder pharmaceutical formulation comprising an oxytocin synthetic peptide, a derivative or analog of said peptide; zinc citrate or zinc chloride, and/or a pharmaceutically acceptable carrier or excipient, wherein the formulation is stable for at least 40 weeks at 40° C. and 75% relative humidity. 2. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein the formulation comprises zinc chloride. 3. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein the pharmaceutically acceptable carrier or excipient is a sugar selected from mannose, mannitol, trehalose, or sorbitol. 4. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein the pharmaceutically acceptable carrier or excipient is polyvinylpyrrolidone, polyethylene glycol, or a diketopiperazine. 5. The inhalable spray-dried powder pharmaceutical formulation of claim 4, wherein the diketopiperazine is fumaryl diketopiperazine or succinyl diketopiperazine. 6. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein the zinc citrate or zinc chloride is in an amount ranging from 100 to 20 equivalents per mole of the oxytocin, the oxytocin analog or derivative thereof. 7. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 200 IU. 8. The inhalable spray-dried powder pharmaceutical formulation of claim 7, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 150 IU. 9. The inhalable spray-dried powder pharmaceutical formulation of claim 7, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 100 IU. 10. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 200 IU. 11. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 150 IU. 12. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 100 IU. 13. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein said oxytocin synthetic peptide, a derivative, or an analog of said peptide is in an amount comprising up to 50 IU. 14. The inhalable spray-dried powder pharmaceutical formulation of claim 1, wherein the formulation comprises zinc citrate. 15. The inhalable spray-dried powder pharmaceutical formulation of claim 1, further comprising an amino acid selected from leucine, isoleucine, trileucine, cysteine, lysine, glycine, arginine, methionine, and histidine. 16. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is leucine. 17. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is isoleucine. 18. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is trileucine. 19. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is cysteine. 20. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is lysine. 21. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is glycine. 22. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is arginine. 23. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is methionine. 24. The inhalable spray-dried powder pharmaceutical formulation of claim 15, wherein the amino acid is histidine.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.